Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of Shorten Gonadotropin-releasing Hormone Agonist Therapy on the Outcome of in Vitro Fertilization-Embryo Transfer in Patients With Endometriosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03006406
Recruitment Status : Unknown
Verified December 2016 by Yingpu Sun, The First Affiliated Hospital of Zhengzhou University.
Recruitment status was:  Recruiting
First Posted : December 30, 2016
Last Update Posted : December 30, 2016
Sponsor:
Information provided by (Responsible Party):
Yingpu Sun, The First Affiliated Hospital of Zhengzhou University

Brief Summary:
Gonadotropin-releasing hormone analogue (GnRH-a) is a synthetic decapeptide compound which can down-regulate pituitary function causing a temporary low estrogen state. Since endometriosis is an estrogen-dependent disease, the use of long-acting GnRH-a can control the growth of endometriosis by inhibiting ovary function.Some scholars have found that, for adenomyosis patients who received a super long protocol (pretreatment of long-acting GnRH-a for 1-2 months) in IVF treatment, the pregnancy outcome is comparable to that of the controls with normal uterus. Thus, the aim of this study is to compare the clinical pregnancy rate in patients treated with GnRH-a for 1, or 2 months.

Condition or disease Intervention/treatment Phase
Clinical Pregnancy Rate Drug: Long term GnRH-a (3.75mg) Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Treatment
Study Start Date : January 2016
Estimated Primary Completion Date : January 2017
Estimated Study Completion Date : January 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Endometriosis

Arm Intervention/treatment
Active Comparator: Long term GnRH-a for 1 month
patient in this group only receive GnRH-a 3.75 for 1 month
Drug: Long term GnRH-a (3.75mg)
patient in this group only receive GnRH-a 3.75 for pituitary down-regulation

Experimental: patient in this group only receive GnRH-a 3.75 for 2 month
patient in this group only receive GnRH-a 3.75 for 2 month
Drug: Long term GnRH-a (3.75mg)
patient in this group only receive GnRH-a 3.75 for pituitary down-regulation




Primary Outcome Measures :
  1. clinical pregnancy rate [ Time Frame: 5 weeks after embryo transfer ]

Secondary Outcome Measures :
  1. Number of oocytes retrieved [ Time Frame: 1 day at oocyte retrieved day ]
  2. 2 pronucleus(2PN)fertilization rate [ Time Frame: 48hours after oocyte retrieved day ]
    Number of 2PN/Matured oocytes



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   22 Years to 42 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • first IVF cycle;
  • with normal ovarian reserve(FSH(10miu/ml; antral follicle count )3)
  • with normal uterine

Exclusion Criteria:

  • Pre-implantation genetic diagnosis cycles;
  • Oocyte donation cycles

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03006406


Contacts
Layout table for location contacts
Contact: Huijuan Kong, M.D. 86-371-67966161 luckyjuanjuan819@126.com

Locations
Layout table for location information
China, Henan
Reproductive Medical Center, First Affiliated Hospital of Zhengzhou University Recruiting
Zhengzhou, Henan, China, 450052
Contact: Yingpu Ms Sun, M.D,PhD    86-13803841888    syp2008@vip.sina.com   
Contact: Zhiqin Mr Bu, MD    86-15981978863    rmczzu@126.com   
Sponsors and Collaborators
The First Affiliated Hospital of Zhengzhou University

Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Yingpu Sun, Director of Reproductive Medical Center,1st Affilated Hospital, Zhengzhou University, The First Affiliated Hospital of Zhengzhou University
ClinicalTrials.gov Identifier: NCT03006406     History of Changes
Other Study ID Numbers: ENDO-1
First Posted: December 30, 2016    Key Record Dates
Last Update Posted: December 30, 2016
Last Verified: December 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Keywords provided by Yingpu Sun, The First Affiliated Hospital of Zhengzhou University:
endometriosis
long term GnRH-a
Additional relevant MeSH terms:
Layout table for MeSH terms
Endometriosis
Genital Diseases, Female
Prolactin Release-Inhibiting Factors
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs